Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation
Arsenic trioxide (As2O3) is one of the most effective therapeutic agents used for patients with acute promyelocytic leukemia (APL). The probable explanation for As2O3-induced cell differentiation is the direct targeting of PML-RARα oncoprotein by As2O3, which results in initiation of PML-RARa degrad...
Main Authors: | , , , , , , |
---|---|
Format: | Online |
Language: | English |
Published: |
Impact Journals LLC
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694856/ |